Pharma & Biotech

Digital experience for pharma and biotech, built for regulated content

Magnolia DXP gives pharma and biotech teams one platform to build modular, pre-approved content and deliver it to healthcare professionals (HCPs) and patients across every channel — with the integrations, permissions, and audit trails that regulated marketing requires.

This is where we collect what our team, our customers, and our implementation partners have learned about digital engagement in pharma and biotech. The posts below cover modular content architecture, HCP portals, the Veeva Vault PromoMats integration, and a four-part series on adopting generative AI in a regulated environment — from where to start, through the decisions that shape the program, to the use cases and the risks. Every capability described here has a named customer behind it.

Modular content architecture: build once, assemble many

Magnolia DXP stores your approved text, imagery, and claims as reusable components rather than finished pages. Teams recombine those components into new assets instead of producing each one from scratch, which is what makes speed and consistency compatible in a market where every asset carries medical, legal, and regulatory (MLR) review. Mark Melton set out how modular approaches work with a DXP in pharma and biotech — the model is Create Once, Publish Everywhere, applied to content that cannot be rewritten casually.

Veeva's own research on modular content puts numbers on the difference: a 50% increase in speed to market, a 20% reduction in content creation costs, and 75% of content approved in a single review cycle. Veeva's Pulse Field Trends data also found new patient starts 2.5 times more likely when representatives use digital content.

Sanofi runs this at global scale: 300 websites migrated onto Magnolia DXP, six legacy CMS platforms retired, a common global template library, 500+ business users trained, 80 agency partners enabled, and content delivery more than 20% faster. Crescendo Collective, a Platinum partner, worked on that program and also built the Advanced Personalization extension available on the Magnolia Marketplace.

Veeva Vault PromoMats orchestration

Magnolia DXP connects directly to Veeva Vault PromoMats, so approved claims, references, and content modules flow into the authoring environment and stay synchronized. Vault PromoMats — used by over 300 pharma and biotech companies — remains the source of truth; when a claim changes there, the change propagates rather than being copied by hand across channels. Eryn Veronesi explained what the integration and the accompanying HCP portal template do, including automatic claims linking and the reference library.

The practical effect is fewer manual re-approval cycles and fewer transcription errors between systems. MLRexpress extends the same idea into the review process itself: it automates submission and removes the manual PDF assembly — the screenshots, the consolidation, the portal uploads — that turns regulatory review into a bottleneck even when content production is fast. Crescendo Collective, which builds these integrations, reports seeing submission handling times cut by up to 90%.

Sanofi is extending this pattern further, with Veeva Vault MedComms — its repository of medical content — planned as the next integration milestone.

HCP and patient portals

Magnolia DXP delivers personalized portals with single sign-on, identity verification, access control, and content encryption — so gated clinical material reaches verified professionals while public pages stay discoverable. Joe Clemente of Crescendo Collective laid out what actually makes an HCP portal work: user-centric design, authoring fast enough to keep pace with clinical change, analytics, and self-curation. Vanessa Dietz covered the wider picture in HCP engagement in the digital era, where the argument is that overly cautious compliance postures undercut digital programs rather than protecting them.

The proof spans audiences. Sanofi personalized 40 HCP portals against user profile data, with Algolia-powered faceted search across dozens of sites. Berlin-Chemie built TheraKey, an interactive patient health portal with a 12-week automated therapy program, unified across five client brands. ISDIN turned the same platform inward, connecting 1,600+ employees through MyISDIN with SAP, SuccessFactors, and Google integrations. VSP moved its Eyefinity brand sites onto Magnolia DXP and now publishes changes in minutes rather than weeks. Digitalya, a solution partner with 60+ life sciences projects across 29 European and Middle Eastern markets, specializes in exactly this portal work.

Governed AI with human review in the loop

Magnolia DXP provides the integration layer for AI — the AI Connector framework, which connects to third-party models from providers such as OpenAI, Anthropic, and AWS Bedrock. Magnolia does not build, train, or operate its own models, and customer content is not shared with model providers for training on AWS pay-as-you-go configurations. What Magnolia DXP contributes is the tooling around the model: prompt controls, provenance, audit trails recording which model was invoked and by whom, and workflows that keep MLR reviewers in the loop before anything publishes. Capabilities built on that layer include Doc-to-Page, Instant Translate, and Magnolia Answers.

Agentic AI is the next step on the same foundation, not a replacement for what came before: the same content model and the same governance, with the ability to act rather than only assist. Each agent runs with human-in-the-loop validation and leaves an audit trail, so a person still decides what publishes.

That governance layer is the reason AI adoption in this sector is a sequence rather than a switch. The four posts below follow it in order: getting started with low-risk internal projects, the key decisions that shape a program (use, boost, or build; provider selection; skills; usage policy; ROI), seven use cases from content generation to translation to customer service, and where the opportunities and risks sit once you are running. Jan Schulte's 2025 trends sets the surrounding context: physician shortages, HCP burnout, and the shift from experimentation to execution.

Berlin-Chemie shows the pattern in production. Its ISA assistant answers COPD patient questions from a curated corpus of 720+ scientific studies — grounded in reviewed source material rather than open generation. A patient- or HCP-facing assistant like this triggers disclosure duties under Article 50 of the EU AI Act, and certain uses in this sector fall into the Act's high-risk category; Magnolia DXP supports machine-readable provenance metadata and customer-configurable disclosure labels, and each use case needs its own legal evaluation. Our EU AI Act statement sets out what the platform provides and where the customer's own obligations begin. IBM iX, a Platinum partner, worked on the Berlin-Chemie program and co-authored our getting-started guide to generative AI in this sector.

Compliance and certifications

Magnolia DXP is ISO 27001:2022 and ENS (High) certified and SOC 2 Type II attested, with GDPR support and AWS regional hosting for EU data residency. Certifications describe how the platform is built and operated; correct implementation in a live environment rests with your team and your implementation partner.

Featured resources

Magnolia DXP for pharma and biotech — the platform view: unifying DAM, CRM, CDP and analytics, building modular content, accelerating MLR review, and delivering HCP and patient portals. Start here if you want the capability map rather than the commentary.

Engaging with healthcare professionals in the digital era — whitepaper on connecting with HCPs as in-person access declines: modular content, the Veeva Vault PromoMats integration, gating content without sacrificing SEO, and what HCP portals need to do. Includes the 20%+ delivery-speed improvement and a 7,000-page migration completed in under two months.

Get started with generative AI in biopharma marketing — co-authored with IBM iX. Top use cases, implementation approaches, the decisions that matter early, and the compliance safeguards to put around them.

How to create HCP portals that actually work — 40 minutes with Alex Jijie (Digitalya) and Tom Vaughton (Varn Health). Research on where pharma and biotech companies fall short of HCP expectations, a walkthrough of a best-in-class portal, and five strategies for optimizing content for both SEO and AI search.

Using generative AI in a compliant, safe, and trusted way — 50 minutes with Jan Hulshoff Pol (Berlin-Chemie), Jan Schulte (Magnolia), Christina Schiffler (IBM iX), and Boris Arendt (Simpliant legal). Risk mitigation, AI governance, and where AI can shorten the MLR review cycle. The closest thing we have to a legal-and-marketing conversation in one room.